Alain Casanova

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland

N. Schur, Arjun Bhadhuri, M. Schwenkglenks, 2021, PharmacoEconomics.